Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


03.10.2022

3 Aliment Pharmacol Ther
1 Ann Intern Med
1 BMC Gastroenterol
8 Clin Gastroenterol Hepatol
8 Dig Dis Sci
6 Eur J Gastroenterol Hepatol
9 Gastroenterology
2 Gut
5 Inflamm Bowel Dis
1 J Clin Gastroenterol
1 J Crohns Colitis
1 Lancet Gastroenterol Hepatol
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. AVNI-BIRON I, Mishael T, Zittan E, Livne-Margolin M, et al
    Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Sep 27. doi: 10.1111/apt.17224.
    PubMed         Abstract available

  2. SHIN A
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1300-1301.
    PubMed        

  3. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1302-1303.
    PubMed        


    Ann Intern Med

  4. MEYER A, Neumann A, Drouin J, Weill A, et al
    Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease : A Nationwide Emulation Trial.
    Ann Intern Med. 2022 Sep 27. doi: 10.7326/M22-0819.
    PubMed         Abstract available


    BMC Gastroenterol

  5. LUO J, Zhong J, Li H, Zhang S, et al
    Translation and evaluation of the simplified Chinese version of the rating form of IBD patient concerns.
    BMC Gastroenterol. 2022;22:426.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  6. LITTLE RD, Ward MG, Sparrow MP
    Letter to the Editor: can subcutaneous infliximab replace dose-intensified intravenous administration in inflammatory bowel disease?
    Clin Gastroenterol Hepatol. 2022 Sep 22. pii: S1542-3565(22)00913.
    PubMed        

  7. DAI C, Jiang M, Huang YH
    Anti-TNF withdrawal in inflammatory bowel disease with endoscopic healing and the Risk of Relapse.
    Clin Gastroenterol Hepatol. 2022 Sep 21. pii: S1542-3565(22)00914.
    PubMed        

  8. HASHASH JG, Desai A, Kochhar GS, Farraye FA, et al
    Efficacy of Paxlovid and Lagevrio for COVID-19 Infection in patients with Inflammatory Bowel Disease: A Propensity Matched Study.
    Clin Gastroenterol Hepatol. 2022 Sep 21. pii: S1542-3565(22)00908.
    PubMed        

  9. PEYRIN-BIROULET L, Rahier JF, Kirchgesner J, Abitbol V, et al
    I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Sep 21. pii: S1542-3565(22)00916.
    PubMed         Abstract available

  10. CHENG D, Kochar BD, Cai T, Ananthakrishnan AN, et al
    Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor alpha Antagonists in Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2022;20:2366-2372.
    PubMed         Abstract available

  11. KOCHAR B, Jylhava J, Soderling J, Ritchie CS, et al
    Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study.
    Clin Gastroenterol Hepatol. 2022;20:2358-2365.
    PubMed         Abstract available

  12. D'HAENS G, Panes J, Louis E, Lacerda A, et al
    Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study.
    Clin Gastroenterol Hepatol. 2022;20:2337-2346.
    PubMed         Abstract available

  13. BACHOUR SP, Shah RS, Lyu R, Nakamura T, et al
    Test Characteristics of Cross-sectional Imaging and Concordance With Endoscopy in Postoperative Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:2327-2336.
    PubMed         Abstract available


    Dig Dis Sci

  14. SUCHMAN K, Luo Y, Grinspan A
    Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort.
    Dig Dis Sci. 2022;67:4866-4873.
    PubMed         Abstract available

  15. SYAL G, Sparrow MP, Velayos F, Cheifetz AS, et al
    Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology.
    Dig Dis Sci. 2022;67:4687-4694.
    PubMed         Abstract available

  16. SIGALA-ROBLES R, Santiago-Lopez L, Hernandez-Mendoza A, Vallejo-Cordoba B, et al
    Peptides, Exopolysaccharides, and Short-Chain Fatty Acids from Fermented Milk and Perspectives on Inflammatory Bowel Diseases.
    Dig Dis Sci. 2022;67:4654-4665.
    PubMed         Abstract available

  17. ZAND A, Stokes Z, Sharma A, van Deen WK, et al
    Artificial Intelligence for Inflammatory Bowel Diseases (IBD); Accurately Predicting Adverse Outcomes Using Machine Learning.
    Dig Dis Sci. 2022;67:4874-4885.
    PubMed         Abstract available

  18. SULTAN K, Trindade AJ
    Concise Commentary: Is Splitting the Difference? Identifying Risk Factors Associated with Suboptimal Bowel Preparation for Colonoscopy Among IBD Patients.
    Dig Dis Sci. 2022;67:4602-4603.
    PubMed        

  19. BARRETT CM, Long MD, Grimm I, Herfarth HH, et al
    Off the Cuff Markers: Surveillance and Endoscopic Approaches for Dysplasia After Ileal Pouch-Anal Anastomosis.
    Dig Dis Sci. 2022;67:4666-4670.
    PubMed        

  20. SONNENBERG A
    Similar Time Trends of Hodgkin Lymphoma, Multiple Sclerosis, and Inflammatory Bowel Disease.
    Dig Dis Sci. 2022 Sep 27. pii: 10.1007/s10620-022-07705.
    PubMed         Abstract available

  21. MIYAZAKI H, Watanabe D, Ito Y, Okamoto N, et al
    Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan.
    Dig Dis Sci. 2022 Sep 30. pii: 10.1007/s10620-022-07703.
    PubMed         Abstract available


    Eur J Gastroenterol Hepatol

  22. FISKE J, Liu E, Limdi JK, Conley TE, et al
    Safety and effectiveness of ustekinumab in elderly Crohn's disease patients.
    Eur J Gastroenterol Hepatol. 2022;34:1132-1139.
    PubMed         Abstract available

  23. EBERL A, Qadri S, Saavalainen P, Sipponen T, et al
    Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022;34:1125-1131.
    PubMed         Abstract available

  24. CASSINOTTI A, Mezzina N, De Silvestri A, Di Paolo D, et al
    Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison study.
    Eur J Gastroenterol Hepatol. 2022 Sep 23. pii: 00042737-990000000-00076.
    PubMed         Abstract available

  25. EBERL A, Qadri S, Saavalainen P, Sipponen T, et al
    Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022 Sep 12. pii: 00042737-990000000-00059.
    PubMed         Abstract available

  26. THEODORAKI E, Orfanoudaki E, Petroulaki E, Foteinogiannopoulou K, et al
    Active smoking is associated with the development of adverse events of biological therapy in patients with inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2022 Sep 12. pii: 00042737-990000000-00073.
    PubMed         Abstract available

  27. PAUPARD T, Gonzalez F, Caron B, Siproudhis L, et al
    Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study.
    Eur J Gastroenterol Hepatol. 2022 Sep 12. pii: 00042737-990000000-00067.
    PubMed         Abstract available


    Gastroenterology

  28. SEGAL JP
    Ustekinumab Versus Adalimumab in Patients With Crohn's Disease.
    Gastroenterology. 2022;163:1115-1116.
    PubMed        

  29. BRENNER TA, Steinway S
    Penile Necrosis in a Patient With Untreated Crohn's Disease.
    Gastroenterology. 2022;163:832-834.
    PubMed        

  30. NGUYEN NH, Solitano V, Vuyyuru SK, MacDonald JK, et al
    Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Gastroenterology. 2022;163:937-949.
    PubMed         Abstract available

  31. GLOBIG AM, Mayer LS, Heeg M, Andrieux G, et al
    Exhaustion of CD39-Expressing CD8(+) T Cells in Crohn's Disease Is Linked to Clinical Outcome.
    Gastroenterology. 2022;163:965-981.
    PubMed         Abstract available

  32. DUNKIN D, Merlino F, Correale C, Yeretssian G, et al
    A Small CEACAM5 Peptide Restores the Protective Function of CD8(+) Regulatory T Cells in Crohn's Disease.
    Gastroenterology. 2022;163:1090-1093.
    PubMed        

  33. GHIBOUB M, Penny S, Verburgt CM, Boneh RS, et al
    Metabolome Changes With Diet-Induced Remission in Pediatric Crohn's Disease.
    Gastroenterology. 2022;163:922-936.
    PubMed         Abstract available

  34. ALLEZ M
    A CEACAM5-derived Peptide Activating CD8(+) Regulatory T Cells: A Future Option for Restoring Mucosal Homeostasis in Crohn's Disease?
    Gastroenterology. 2022;163:822-824.
    PubMed        

  35. UNGARO RC, Kappelman MD
    Reappraisal of COVID-19 Risk for Patients with Inflammatory Bowel Disease (IBD): Withdrawal of the British Society of Gastroenterology IBD Risk Grid.
    Gastroenterology. 2022 Sep 23. pii: S0016-5085(22)01069.
    PubMed        

  36. TANG J, Wang JP, Chao K
    An Unusual Cause of Chronic Pancreatitis in a Patient with Crohn's Disease.
    Gastroenterology. 2022 May 18. pii: S0016-5085(22)00521.
    PubMed        


    Gut

  37. MANSOOR E, Martin SA, Perez A, Nguyen VQ, et al
    Epidemiology of inflammatory bowel disease in men with high-risk homosexual activity.
    Gut. 2022 Sep 1. pii: gutjnl-2022-328218. doi: 10.1136/gutjnl-2022-328218.
    PubMed        

  38. SUDHAKAR P, Wellens J, Verstockt B, Ferrante M, et al
    Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?
    Gut. 2022 Sep 28. pii: gutjnl-2022-328221. doi: 10.1136/gutjnl-2022-328221.
    PubMed         Abstract available


    Inflamm Bowel Dis

  39. TANAKA M, Kawakami A, Sakagami K, Terai T, et al
    Development and Validation of a Japanese Version of the Inflammatory Bowel Disease Self-efficacy Scale and Cross-culture Study in Japan and the United States.
    Inflamm Bowel Dis. 2022 Sep 27. pii: 6723730. doi: 10.1093.
    PubMed         Abstract available

  40. MULES TC, Swaminathan A, Hirschfeld E, Borichevsky GM, et al
    The Impact of Disease Activity on SD and ED in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2022 Sep 27. pii: 6724308. doi: 10.1093.
    PubMed         Abstract available

  41. TANNER S, Katz J, Cominelli F, Regueiro M, et al
    Inflammatory Bowel Disease and Helicobacter pylori: Protective or Present?
    Inflamm Bowel Dis. 2022 Sep 28. pii: 6726164. doi: 10.1093.
    PubMed        

  42. SAFARPOUR AR, Shojaei-Zarghani S, Mehrabi M, Keshtkar AA, et al
    Reply to "Biologics Are Effective in the Management of Inflammatory Bowel Disease Following Liver Transplantation in Combination With Antirejection Therapy".
    Inflamm Bowel Dis. 2022 Sep 29. pii: 6731245. doi: 10.1093.
    PubMed        

  43. VUYYURU SK, Brahmania M, Arab JP, Jairath V, et al
    Biologics Are Effective in the Management of Inflammatory Bowel Disease Following Liver Transplantation in Combination With Antirejection Therapy.
    Inflamm Bowel Dis. 2022 Sep 29. pii: 6731264. doi: 10.1093.
    PubMed        


    J Clin Gastroenterol

  44. DALAL RS, Mitri J, Goodrick H, Allegretti JR, et al
    Risk of Gastrointestinal Infections After Initiating Vedolizumab and Anti-TNFalpha Agents for Ulcerative Colitis.
    J Clin Gastroenterol. 2022 Aug 4. pii: 00004836-990000000-00040.
    PubMed         Abstract available


    J Crohns Colitis

  45. SCHOEFS E, Vermeire S, Ferrante M, Sabino J, et al
    What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study.
    J Crohns Colitis. 2022 Sep 27. pii: 6722595. doi: 10.1093.
    PubMed         Abstract available


    Lancet Gastroenterol Hepatol

  46. SELIM R, Wellens J, Brann S, Marlow L, et al
    Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy.
    Lancet Gastroenterol Hepatol. 2022 Sep 21. pii: S2468-1253(22)00302.
    PubMed        


    Proc Natl Acad Sci U S A

  47. GOMEZ-NGUYEN A, Gupta N, Sanaka H, Gruszka D, et al
    Chronic stress induces colonic tertiary lymphoid organ formation and protection against secondary injury through IL-23/IL-22 signaling.
    Proc Natl Acad Sci U S A. 2022;119:e2208160119.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: